J
Joseph J. Eron
Researcher at University of North Carolina at Chapel Hill
Publications - 569
Citations - 49427
Joseph J. Eron is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 99, co-authored 511 publications receiving 44857 citations. Previous affiliations of Joseph J. Eron include Duke University.
Papers
More filters
Journal ArticleDOI
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Joseph J. Eron,Chloe Orkin,Douglas Cunningham,Federico Pulido,Frank A. Post,Stéphane De Wit,Erkki Lathouwers,Veerle Hufkens,John Jezorwski,Romana Petrovic,Kimberley Brown,Erika Van Landuyt,Magda Opsomer,S De Wit,Eric Florence,Michel Moutschen,E. Van Wijngaerden,Linos Vandekerckhove,Bernard Vandercam,Jason Brunetta,Brian Conway,Marina B. Klein,D. Murphy,Anita Rachlis,S. Shafran,S. Shafran,Sharon Walmsley,Faiza Ajana,Laurent Cotte,P.-M. Girardy,Christine Katlama,J.-M. Molina,I. Poizot-Martin,F Raffi,D. Rey,Jacques Reynes,E. Teicher,Yazdan Yazdanpanah,J Gasiorowski,W. Halota,A. Horban,A. Piekarska,A. Witor,Jose R. Arribas,Ignacio Pérez-Valero,Juan Berenguer,José L. Casado,Gatell Jm,Félix Gutiérrez,M. J. Galindo,Mar Gutierrez,José Antonio Iribarren,Hernando Knobel,Eugenia Negredo,Juan A. Pineda,Daniel Podzamczer,J. Portilla Sogorb,F. Pulido,C. Ricart,Antonio Rivero,I. Santos Gil,Anders Blaxhult,Leo Flamholc,Magnus Gisslén,A. Thalme,Jan Fehr,Andri Rauch,Marcel Stoeckle,Amanda Clarke,Brian Gazzard,M.A. Johnson,C. Orkin,F. Post,Andrew Ustianowski,L. Waters,J. Bailey,P. Benson,L. Bhatti,I. Brar,U. F. Bredeek,Cynthia Brinson,Gordon Crofoot,D. Cunningham,Edwin DeJesus,Craig A. Dietz,Robin Dretler,J. J. Eron,Franco Antonio Felizarta,Carl J. Fichtenbaum,Joel E. Gallant,J. Gathe,Debbie Hagins,S. Henn,W.K. Henry,G. Huhn,Mamta K. Jain,C. Lucasti,Claudia Martorell,Cheryl McDonald,Anthony Mills,Javier O Morales-Ramirez,Karam Mounzer,Ronald Nahass,H. Olivet,Olayemi Osiyemi,D. Prelutsky,Moti Ramgopal,B. Rashbaum,Gary Richmond,Peter Ruane,A. Scarsella,A. Scribner,P. Shalit,David Shamblaw,J. Slim,K. Tashima,G. Voskuhl,D. Ward,A. Wilkin,J. de Vente +119 more
TL;DR: EMERALD week 96 results confirm the efficacy, high genetic barrier to resistance and safety benefits of D/C/F/TAF as well as the lack of a control arm in the week 96 analysis.
Journal ArticleDOI
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Stephanie A. Ruderman,Heidi M. Crane,Robin M. Nance,Bridget M. Whitney,Barbara N Harding,Kenneth H. Mayer,Richard D. Moore,Joseph J. Eron,Elvin Geng,William C. Mathews,B Rodriguez,Amanda L. Willig,Greer A Burkholder,Sara Lindström,Brian R. Wood,Ann C. Collier,Vani Vannappagari,Cassidy Henegar,Jean van Wyk,Lloyd Curtis,Michael S. Saag,Mari M. Kitahata,Joseph A.C. Delaney,Joseph A.C. Delaney +23 more
TL;DR: There is heterogeneity between regimens in weight gain following ART initiation among previously ART-naïve PLWH; there is greater gain among PLWH taking newer INSTIs (DTG, BIC, and DRV-based regimens.
Journal ArticleDOI
Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006-2009.
Christina Ludema,Stephen R. Cole,Joseph J. Eron,Andrew Edmonds,G. Mark Holmes,Kathryn Anastos,Jennifer Cocohoba,Mardge H. Cohen,Hannah L.F. Cooper,Elizabeth T. Golub,Seble Kassaye,Deborah Konkle-Parker,Lisa R. Metsch,Joel Milam,Tracey E. Wilson,Adaora A. Adimora +15 more
TL;DR: Although women with private insurance are most likely to be virally suppressed, ADAP also contributes to viral load suppression.
Journal ArticleDOI
The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials
TL;DR: In two independent studies in patients with limited antiretroviral treatment experience, remarkably similar results were obtained when 3TC/zidovudine in combination was compared to zidvudine monotherapy, demonstrating sustained antireTroviral and immunological effects of the combination over the 48 and 52 weeks of study.
Journal ArticleDOI
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Ashley J Mayo,Chelu K. Mfalila,Haitao Chu,Anna C. Barry,Joann D. Kuruc,Kara S. McGee,Melissa Kerkau,Joe Sebastian,Susan A. Fiscus,David M. Margolis,Charles B. Hicks,Guido Ferrari,Joseph J. Eron +12 more
TL;DR: Once-daily emtricitabine/tenofovir/efavirenz initiated during AHI achieves rapid and sustained HIV suppression during this highly infectious period.